WO2011135141A4 - Modified oligonucleotides as regulators of gene expression - Google Patents
Modified oligonucleotides as regulators of gene expression Download PDFInfo
- Publication number
- WO2011135141A4 WO2011135141A4 PCT/ES2011/070296 ES2011070296W WO2011135141A4 WO 2011135141 A4 WO2011135141 A4 WO 2011135141A4 ES 2011070296 W ES2011070296 W ES 2011070296W WO 2011135141 A4 WO2011135141 A4 WO 2011135141A4
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parni
- page
- new
- compound according
- group
- Prior art date
Links
- 0 CC(C(CO*)NC(C1=C2C=CC=CC2Cc2c1cccc2)=O)O Chemical compound CC(C(CO*)NC(C1=C2C=CC=CC2Cc2c1cccc2)=O)O 0.000 description 6
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
Abstract
Claims
62 62
DECLARACION SEGUN EL ARTICULO 19 (1 ) DECLARATION ACCORDING TO ARTICLE 19 (1)
(1 ) Se aporta una serie completa de reivindicaciones que reemplazan a las reivindicaciones iniciatmente presentadas, como sigue: (1) A complete series of claims is presented that replace the claims presented initially, as follows:
A) hojas sustitutivas 49, 50 y 51 , que corresponden a las páginas originales de la memoria con la misma numeración en las que están incluidas las reivindicaciones 1 a 16 y parte de la reivindicación 1 7; y A) substitute sheets 49, 50 and 51, corresponding to the original pages of the memory with the same numbering in which claims 1 to 16 and part of claim 1 7 are included; Y
B) nuevas hojas 52 a 58 de memoria, en las que se ha modificado el juego de reivindicaciones añadiendo las nuevas reivindicaciones 17 (parte omitida) a 43, junto con hoja 59 renumerada, que corresponde al Resumen (antigua hoja 52). B) new sheets 52 to 58 of memory, in which the set of claims has been modified by adding the new claims 17 (part omitted) to 43, together with renumbered sheet 59, corresponding to the Summary (former sheet 52).
(2) Las reivindicaciones 1 a 16 sustitutivas corresponden a las reivindicaciones originales con la misma numeración, por lo que tienen apoyo en la memoria tal cual se presentó. (2) Substitute claims 1 to 16 correspond to the original claims with the same numbering, so they have support in the memory as it was presented.
(3) La parte omitida de la reivindicación 17, así como el contenido de las nuevas reivindicaciones 1 8 a 43 tienen soporte en la memoria original, como sigue: (3) The omitted part of claim 17, as well as the content of the new claims 1 to 43 are supported in the original memory, as follows:
- La reivindicación 1 7 completada: desde página 8, linee 28 a página 9. - Claim 1 7 completed: from page 8, line 28 to page 9.
- La nueva reivindicación 8: desde página 9, línea 1 3 a página 10, línea 1 6, - The new claim 8: from page 9, line 1 3 to page 10, line 1 6,
- La nueva reivindicación 1 9: página 1 1 , líneas 1 -9. - The new claim 1 9: page 1 1, lines 1 -9.
- La nueva reivindicación 20: página 1 1 , líneas 1 1 - 1 3. - The new claim 20: page 1 1, lines 1 1 - 1 3.
- La nueva reivindicación 21 : página 1 1 , líneas 1 3-14. - The new claim 21: page 1 1, lines 1 3-14.
- La nueva reivindicación 22: página 1 1 , líneas 1 6-1 7. - The new claim 22: page 1 1, lines 1 6-1 7.
■ La nueva reivindicación 23: página 1 1 , líneas 19-23. ■ The new claim 23: page 1 1, lines 19-23.
- Le nueva reivindicación 24: desde página 1 1 , línea 26 a página 1 2. - The new claim 24: from page 1 1, line 26 to page 1 2.
- Las nuevas reivindicaciones 25, 26 y 27: página 1 2, líneas 3-6. A este respecto, debe tenerse en cuente que esta parte del texto se refiere a "los compuestos de la invención". Estos se describen en la página 3, linea 22 a página 4, línea 1 1 de la memoria original, donde se afirma que "Y es un dúplex de pARNi", al igual que en la reivindicación 1 de la que dependen estas nuevas reivindicaciones 25-27, - The new claims 25, 26 and 27: page 1 2, lines 3-6. In this regard, it should be kept in mind that this part of the text refers to "the compounds of the invention". These are described on page 3, line 22 to page 4, line 1 1 of the original memory, where it is stated that "Y is a pRNA duplex", as in claim 1 on which these new claims depend. -27,
- La nueva reivindicación 28: página 1 2, línea 8-1 8. - The new claim 28: page 1 2, line 8-1 8.
- La nueva reivindicación 29: desde página 12, línea 20 a página 1 3, línea 1 1 . - The new claim 29: from page 12, line 20 to page 1 3, line 1 1.
- La nueva reivindicación 30: página 13, líneas 1 1 - 1 5. - The new claim 30: page 13, lines 1 1 - 1 5.
- La nueva reivindicación 31 : página 13, líneas 25-29. - The new claim 31: page 13, lines 25-29.
- La nueva reivindicación 32: desde página 3, línea 22 a página 4, línea 1 1 . - The new claim 32: from page 3, line 22 to page 4, line 1 1.
- La nueva reivindicación 33: página 4, lincas 6-30. - The new claim 33: page 4, lines 6-30.
- La nueva reivindicación 34: página 14, líneas 5-8. - The new claim 34: page 14, lines 5-8.
- La nueva reivindicación 35: página 14, líneas 10-14, 63 - The new claim 35: page 14, lines 10-14, 63
- La nueva reivindicación 36; página 1 , líneas 1 5-19. - The new claim 36; page 1, lines 1 5-19.
- La nueva reivindicación 37: página 14, líneas 21 -24. - The new claim 37: page 14, lines 21 -24.
- La nueva reivindicación 38: página 5, líneas 1 -3 y página 1 6, líneas 2-4. - The new claim 38: page 5, lines 1 -3 and page 1 6, lines 2-4.
- La nueva reivindicación 39: página 1 6, líneas 1 6-17. - The new claim 39: page 1 6, lines 1 6-17.
- La nueva reivindicación 40: página 16, líneas 1 9-26. - The new claim 40: page 16, lines 1 9-26.
- La nueva reivindicación 41 : página 5, líneas 5-7. - The new claim 41: page 5, lines 5-7.
- La nueva reivindicación 42: página 17, líneas 1 -2. - The new claim 42: page 17, lines 1 -2.
- La nueva reivindicación 43: página 16, líneas 28-31 . - The new claim 43: page 16, lines 28-31.
(4) En vista del punto anterior, se considera que las modificaciones presentadas son aceptables de acuerdo con la Ley PCT y solventan la objeción/observación hecha por la Administración encargada respecto a la reivindicación 17 (incompleta). Asimismo, a la vista del Informe de Búsqueda Internacional y de la Opinión escrita emitidas por la OEPM como Administración encargada, en las que se otorga novedad y altura Inventiva a las reivindicaciones originales 1 a 16 (ver Recuadro V.1 del Informe de Búsqueda Internacional), se considera que modificaciones que se presentan son patentables. (4) In view of the previous point, it is considered that the modifications presented are acceptable in accordance with the PCT Law and resolve the objection / observation made by the Administration in charge with respect to claim 17 (incomplete). Likewise, in view of the International Search Report and the written Opinion issued by the OEPM as the Responsible Administration, which grants novelty and inventiveness to the original claims 1 to 16 (see Box V.1 of the International Search Report). ), it is considered that modifications that are presented are patentable.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES201030614A ES2372237B1 (en) | 2010-04-27 | 2010-04-27 | MODIFIED OLIGONUCLEOIDS AS REGULATORS OF GENE EXPRESSION. |
ESP201030614 | 2010-04-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011135141A1 WO2011135141A1 (en) | 2011-11-03 |
WO2011135141A4 true WO2011135141A4 (en) | 2012-01-05 |
Family
ID=44860917
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2011/070296 WO2011135141A1 (en) | 2010-04-27 | 2011-04-26 | Modified oligonucleotides as regulators of gene expression |
Country Status (2)
Country | Link |
---|---|
ES (1) | ES2372237B1 (en) |
WO (1) | WO2011135141A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11878978B1 (en) | 2023-09-06 | 2024-01-23 | King Faisal University | Pyrrolo[2,3-c]quinoline compounds as CK2 inhibitors |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2406568B (en) * | 2002-02-20 | 2005-09-28 | Sirna Therapeutics Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
CA2500224C (en) * | 2002-09-25 | 2015-04-28 | University Of Massachusetts | In vivo gene silencing by chemically modified and stable sirna |
GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2010
- 2010-04-27 ES ES201030614A patent/ES2372237B1/en not_active Expired - Fee Related
-
2011
- 2011-04-26 WO PCT/ES2011/070296 patent/WO2011135141A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
ES2372237B1 (en) | 2013-01-24 |
ES2372237A1 (en) | 2012-01-17 |
WO2011135141A1 (en) | 2011-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7077254B2 (en) | Novel lipids and compositions for delivering therapeutic agents | |
JP2021020928A (en) | Targeting lipids | |
JP6356171B2 (en) | PEGylated lipids and their use for drug delivery | |
JP6250543B2 (en) | Dialiphatic substituted PEGylated lipids | |
ES2749426T3 (en) | Nucleic Acid Administration Methods and Compositions | |
Allain et al. | Self-assembled nucleolipids: from supramolecular structure to soft nucleic acid and drug delivery devices | |
CA2783372C (en) | Compositions for nucleic acid delivery | |
JP2023134433A (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
RU2571218C2 (en) | Sirna conjugate and preparation method thereof | |
CN108136040B (en) | Multiligand agents for drug delivery | |
ES2901102T3 (en) | Method for preparing a polymeric micelle containing anionic drug | |
ES2799409T3 (en) | Cationic lipid | |
NZ728517A (en) | Compositions and methods for modulating ttr expression | |
CN107075516A (en) | Double-stranded RNA reagent through modification | |
RU2015119411A (en) | ANTI-SENSE COMPOUNDS CONJUGATES AIMED AT APOLIPOPROTEIN IN | |
BR112020008546A2 (en) | oligonucleotide constructs and their uses | |
US9393309B2 (en) | Self-gelatinizable nucleic acid | |
JP2009542582A5 (en) | ||
JPWO2016152767A1 (en) | CpG spacer oligonucleotide-containing complex having immunostimulatory activity and use thereof | |
WO2011135141A4 (en) | Modified oligonucleotides as regulators of gene expression | |
KR101685304B1 (en) | Nanoliposome for liver-targeting RNA interference delivery | |
CN117202895A (en) | Lipid compounds and lipid nanoparticle compositions | |
Blagbrough et al. | siRNA and Gene Formulation for Efficient Gene Therapy | |
ES2368300B1 (en) | LIPOPHYLIC DERIVATIVES OF NUCLEIC ACIDS. | |
AU2022201011A1 (en) | Targeting lipids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11774453 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase in: |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11774453 Country of ref document: EP Kind code of ref document: A1 |